UAE SALES CONFERENCE

“Together We Exceed”

10th – 12th November 2009

RAK Cove Rotana
Summary of Q3 results

Portfolio diversification and investment in key areas drives return to

sales growth: Emerging markets (+25%); Japan (+19%) and
Consumer Healthcare (+8%)
Further growth expected in Q4 2009 including significant sales of
influenza products
US sales -12% primarily due to continued adverse impact of generic
competition
Significant progress made to expand new vaccines portfolio:
Cervarix approved in USA and Japan; Pandemrix approved in Europe.
Major new contract secured in Brazil for Synflorix
Pipeline momentum sustained with 30 assets in late-stage
development: US approvals of Votrient and Arzerra
Sales in Emerging Markets now represent 14% of pharmaceutical
turnover compared to 12% this time last year. Growth is being driven
through Seretide, Augmentin and Vaccines, and through newly
acquired products, which contributed over £35 million this quarter.
To Market Achievement YTD Sept 2009

YTD Sept 2009 MENA

£M Ach % Gr

TOTAL 633.5 26%

Vaccines 75.5 24%

Augmentin 90.8 21%

Seretide 86.3 22%

Avandia family 16.1 -3%

CNS 35.0 1%

UCB 22.0 -
To Market Achievement YTD Sept 2009

YTD Sept 2009 GNE

£M Ach % Gr
TOTAL 93.4 30%
Vaccines 19.7 20%
Augmentin 14.0 6%
Seretide 5.2 -3%
Avandia family 1.7 -11%
CNS 3.8 4%
Zinnat 4.3 -13%
Oncology 3.0 17%
UCB 10.1 -
To Market Achievement YTD Sept 2009

YTD Sept 2009 Gulf

£M Ach % Gr

TOTAL 69.3 33%

Vaccines 13.2 30%

Augmentin 10.3 8%

Seretide 3.7 -12%

Avandia family 1.1 -41%

CNS 2.2 11%

Zinnat 3.9 -19%

Oncology 1.8 -18%

UCB 9.2 -
Strategic priorities and plans

Strategic priorities Plans

1. Drive growth in Rx business in core markets

2. Deliver ambitious vaccines forecast
Grow a diversified, 3. Significantly grow consumer healthcare business
global business 4. Fulfil growth potential of emerging markets
5. Drive expansion of Japan business
6. Explore further growth enhancing opportunities

7. Increase flow, enhance quality, drive reimbursement

Deliver more 8. Significantly grow biopharm capability
products of value 9. Enhance productivity for Drug Discovery including externalisation
10. Simplifying Clinical R&D

11. Evolve commercial model to empower markets

12. Transforming GMS
Simplify the 13. Simplify support functions and fixed asset base
operating model 14. Simplify the planning process
15. Improve working capital

16. Create a culture of individual empowerment

Individual empowerment 17. Create a talent organisation

18. Create a sustainable licence to operate and adopt the

Build trust 'high ground' in how we conduct our business
Opportunity

Stiefel

UCB and Aspen

SP

BMS Dr. Reddy

ViiV
Healthcare
Filling the gap

2009 £000's UAE KWT QATAR BAH YEMEN OMAN TOTAL

TOTAL 09 F2 BUDGET 42,287 15,466 9,029 6,997 6,201 5,897 85,877
% OF CONT 49% 18% 11% 8% 7% 7%
AVANDIA FAMILY ACH 1,893 112 160 177 27 67 2,436
% OF CONT 78% 5% 7% 7% 1% 3%
SERETIDE ACH 2,802 2,403 910 412 - 410 6,937
% OF CONT 40% 35% 13% 6% 0% 6%
AUGMENTIN ACH 7,065 1,983 1,510 586 1,044 860 13,048
% OF CONT 54% 15% 12% 4% 8% 7%
ZINNAT ACH 3,106 1,122 820 450 381 272 6,151
% OF CONT 50% 18% 13% 7% 6% 4%
ANESTHESIA ACH 814 894 496 263 87 221 2,775
% OF CONT 29% 32% 18% 9% 3% 8%
LAMICTAL/KEPPRA ACH 1,447 1,931 316 304 100 302 4,400
% OF CONT 33% 44% 7% 7% 2% 7%
SEROXAT ACH 358 316 172 134 86 245 1,311
% OF CONT 27% 24% 13% 10% 7% 19%

Less by 1 or 2% Equal/More by 1 or 2%
Less by 3% or more Equal/More than 3%
Filling the gap (contd.)

2009 £000's UAE KWT QATAR BAH YEMEN OMAN TOTAL

TOTAL 09 F2 BUDGET 42,287 15,466 9,029 6,997 6,201 5,897 85,877
% OF CONT 49% 18% 11% 8% 7% 7%
VACCINES ACH 10,475 3,251 1,697 2,773 3,115 1,659 22,970
% OF CONT 46% 14% 7% 12% 14% 7%
ANTIVIRAL ACH 6,346 697 221 694 - 310 8,268
% OF CONT 77% 8% 3% 8% 0% 4%
GASTRO ACH 956 660 344 73 153 167 2,353
% OF CONT 41% 28% 15% 3% 7% 7%
FLIXONASE/AVAMYS ACH 1,526 644 190 157 13 50 2,580
% OF CONT 59% 25% 7% 6% 1% 2%
ONCOLOGY ACH 1,061 977 276 151 27 104 2,596
% OF CONT 41% 38% 11% 6% 1% 4%
BACTROBAN ACH 608 215 118 56 2 72 1,071
% OF CONT 57% 20% 11% 5% 0% 7%
AMOXIL ACH 830 102 128 65 443 276 1,844
% OF CONT 45% 6% 7% 4% 24% 15%
XYZAL/ZYRTEC ACH 1,827 1,869 520 143 209 220 4,788
% OF CONT 38% 39% 11% 3% 4% 5%

Less by 1 or 2% Equal/More by 1 or 2%
Less by 3% or more Equal/More than 3%
Incentives

Annual Incentive
Exceedership
Excellence Recognition Award
PAL Incentive
WOW
GNE Field Force Pay 4 Performance

2009

TotalCash TotalReward
 P4P Vision

• We have a number of incentive schemes

• Confusion and Consistency on eligibility and implementation

Go To
• Simple

• Key Differentiation for Excellent Performance

• Aligned with the GSK Global Bonus Plans & Commercial
targets
• Promoting Recognition that is not only Financial.
• Measures are both financial and behavioural
 GNE Field Force 2009
Pay for Performance (P4P)

Two elements to
the scheme

Annual Reward AllStars Reward

Annual Reward AllStars Reward

Reward based on performance
vs. targets Annual Incentive Trip
 Eligibility

• All Field Force Employees within the D band

• Field Force Employees who transfer between markets will be
assessed on their achievements in both markets and then an
overall rating and achievement will be confirmed.
• Any new employees starting after the 1st January will have their
targets set for the period that they have in role that year.
• Award year is 1st January to 31st December
 GNE Field Force Sales P4P - Annual Reward

• How much can a representative earn through the Primary Care Salesforce Annual Reward?

Vs Target (In Market Sales) Award

Level (base pay)

95% 2 weeks
98% 3 weeks
100% 4 weeks
105% 8 weeks
110% 12
weeks
115% 16
weeks
120% 18
weeks
125% 20
weeks
 ALLSTARS

The recognition incentive programme

 AllStars Event

P4P

Top 10 employees across GNE & Partners

Overseas Event hosted

by a member of the
Senior Management
Team
Thank you